FindTrial
Sign In

A phase I study of LEE011 in Asian patients with advanced solid tumors

A phase I study of LEE011 in Asian patients with advanced solid tumors

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222122
Enrollment
Unknown
Registered
2013-06-20
Start date
2013-06-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

Interventions

investigational material(s) Generic name etc : LEE011 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with a histologically confirmed diagnosis of a solid tumor that have progressed despite standard therapy or for which no further effective standard treatment is available - ECOG performance status of 0 - 1 - Good organ (hepatic, renal, bone marrow) function at screening visit - A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy and recovery from all reversible AEs of previous anti-cancer therapies

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026